Samsung Bioepis Discusses Interchangeability And Adalimumab
Regulatory Chief Voices Support For Making All FDA-Approved Biosimilars Interchangeable
As Samsung Bioepis seeks a US interchangeability designation for its Organon-partnered Hadlima adalimumab biosimilar, the firm’s regulatory affairs chief Byoungin Jung talks to Generics Bulletin about the significance of interchangeability for US biosimilars – and the firm’s support for legislative efforts to have all US approved biosimilars automatically designated as interchangeable.
You may also be interested in...
Amgen’s Amjevita, the first biosimilar of Humira to launch in the US, hasn’t made headway into the US market, according to Samsung Bioepis’ quarterly market report on the US biosimilars market.
Citing low risk of a clinically impactful immunogenic response from systemic anti-drug antibodies and intraocular inflammation when alternating between Coherus’ Cimerli and Genentech’s reference product ranibizumab, US FDA says a switching study would not be informative.
Samsung Bioepis has celebrated becoming the first developer to obtain approvals for both Lucentis and Eylea biosimilars, after its SB15 aflibercept candidate was approved in Korea.